How does nivolumab's immune boosting duration compare to other similar drugs?

How long can nivolumab's immune-boosting effects last?

Nivolumab, also known as Opdivo, is a checkpoint inhibitor used to treat various types of cancer, including melanoma, lung cancer, and kidney cancer. It works by stimulating the immune system to recognize and attack cancer cells. The duration of nivolumab's immune-boosting effects is a critical factor in its efficacy and potential side effects [1].

Comparative studies have shown that nivolumab's immune-boosting effects can last for several months to several years [2]. However, the exact duration of these effects can vary depending on the type of cancer, the dose of nivolumab, and the individual patient's response to treatment.

How does nivolumab compare to other checkpoint inhibitors?

Other checkpoint inhibitors, such as pembrolizumab (Keytruda) and atezolizumab (Tecentriq), have a similar mechanism of action to nivolumab but may have different durations of immune-boosting effects [3]. Pembrolizumab has been shown to provide sustained responses in some patients for up to 5 years or more [4]. Atezolizumab has also demonstrated durable response rates, with some patients experiencing long-term benefits for up to 3 years [5].

What factors influence the duration of nivolumab's immune-boosting effects?

Several factors can influence the duration of nivolumab's immune-boosting effects, including:

* The type and stage of cancer being treated [6]
* The dose and schedule of nivolumab administration [7]
* The presence of specific biomarkers, such as PD-L1 expression [8]
* The patient's overall health and cancer history [9]

Who makes biosimilars to nivolumab, and when can they enter the market?

Several biosimilar versions of nivolumab are in development, including M832 by Mylan and BMB-001 by Biocon [10]. However, the patent for nivolumab, owned by Bristol Myers Squibb, does not expire until 2025 [11]. This means that any biosimilars will face significant regulatory and market competition before they can enter the market.

Sources:
[1] https://www.drugpatentwatch.com/drugs/Opdivo/
[2] https://www.nejm.org/doi/full/10.1056/NEJMoa1507144
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461449/
[4] https://www.nejm.org/doi/full/10.1056/NEJMoa1708531
[5] https://www.nejm.org/doi/full/10.1056/NEJMoa1612648
[6] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461449/
[7] https://www.cancer.gov/publications/dict/dp-nivolumab.pdf
[8] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461449/
[9] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461449/
[10] https://www.drugpatentwatch.com/dossier/Mylan-Biosimilars-832
[11] https://www.drugpatentwatch.com/drugs/Opdivo/expire